445 related articles for article (PubMed ID: 17982632)
21. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC.
Baek YH; Lee SW; Jeong YJ; Jeong JS; Roh YH; Han SY
Hepatogastroenterology; 2015; 62(138):383-8. PubMed ID: 25916068
[TBL] [Abstract][Full Text] [Related]
22. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
[TBL] [Abstract][Full Text] [Related]
23. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
24. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
25. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma.
Wang XL; Li H; Wang QS; Zhang XL
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1087-91, 1095. PubMed ID: 16939890
[TBL] [Abstract][Full Text] [Related]
28. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
29. Whole-body F-18 FDG PET for hepatocellular carcinoma patients after interventional treatment.
Cheng MF; Wu YW; Tzen KY; Huang YH; Yen RF
Neoplasma; 2007; 54(4):342-7. PubMed ID: 17822325
[TBL] [Abstract][Full Text] [Related]
30. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.
Bernstine H; Braun M; Yefremov N; Lamash Y; Carmi R; Stern D; Steinmetz A; Sosna J; Groshar D
Radiology; 2011 Aug; 260(2):503-10. PubMed ID: 21555347
[TBL] [Abstract][Full Text] [Related]
31. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning.
Blokhuis TJ; van der Schaaf MC; van den Tol MP; Comans EF; Manoliu RA; van der Sijp JR
Scand J Gastroenterol Suppl; 2004; (241):93-7. PubMed ID: 15696856
[TBL] [Abstract][Full Text] [Related]
32. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
Lin WY; Tsai SC; Hung GU
Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
[TBL] [Abstract][Full Text] [Related]
33. [Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein].
Chen Z; Liang H; Zhang X; Wang X; Chen W; Shi X; Yi C; Rao L
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1615-9. PubMed ID: 23174588
[TBL] [Abstract][Full Text] [Related]
34. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
[TBL] [Abstract][Full Text] [Related]
35. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
[TBL] [Abstract][Full Text] [Related]
37. Clinical Value of 18F-FDG PET/CT in Detecting Adrenal Metastasis in Patients with Hepatocellular Carcinoma.
Lin Y; Jeng LB; Wang HY; Tsai SC; Lin WY; Kao CH
Technol Cancer Res Treat; 2015 Oct; 14(5):593-9. PubMed ID: 24945368
[TBL] [Abstract][Full Text] [Related]
38. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
[TBL] [Abstract][Full Text] [Related]
39. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
40. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
